Literature DB >> 14668447

Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation.

Jin Ye1, Chunfu Wang, Rhea Sumpter, Michael S Brown, Joseph L Goldstein, Michael Gale.   

Abstract

Hepatitis C virus (HCV) RNA replication depends on viral protein association with intracellular membranes, but the influence of membrane composition on viral replication is unclear. We report that HCV RNA replication and assembly of the viral replication complex require geranylgeranylation of one or more host proteins. In cultured hepatoma cells, HCV RNA replication was disrupted by treatment with lovastatin, an inhibitor of 3-hydroxy-3-methyglutaryl CoA reductase, or with an inhibitor of protein geranylgeranyl transferase I, each of which induced the dissolution of the HCV replication complex. Viral replication was not affected by treatment of cells with an inhibitor of farnesyl transferase. When added to lovastatin-treated cells, geranylgeraniol, but not farnesol, restored replication complex assembly and viral replication. Inasmuch as the HCV genome does not encode a canonical geranylgeranylated protein, the data suggest the involvement of a geranylgeranylated host protein in HCV replication. Inhibition of its geranylgeranylation affords a therapeutic strategy for treatment of HCV infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14668447      PMCID: PMC307659          DOI: 10.1073/pnas.2237238100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

Review 1.  Hepatitis C therapeutics: current status and emerging strategies.

Authors:  Seng-Lai Tan; Arnim Pause; Yuguang Shi; Nahum Sonenberg
Journal:  Nat Rev Drug Discov       Date:  2002-11       Impact factor: 84.694

Review 2.  Future therapy of hepatitis C.

Authors:  John G McHutchison; Keyur Patel
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

3.  Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome.

Authors:  Patrizia Farci; Rita Strazzera; Harvey J Alter; Stefania Farci; Daniela Degioannis; Alessandra Coiana; Giovanna Peddis; Francesco Usai; Giancarlo Serra; Luchino Chessa; Giacomo Diaz; Angelo Balestrieri; Robert H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-05       Impact factor: 11.205

Review 4.  Epidemiology of hepatitis C: geographic differences and temporal trends.

Authors:  A Wasley; M J Alter
Journal:  Semin Liver Dis       Date:  2000       Impact factor: 6.115

5.  Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells.

Authors:  Masanori Ikeda; MinKyung Yi; Kui Li; Stanley M Lemon
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

6.  Genomic analysis of the host response to hepatitis C virus infection.

Authors:  Andrew I Su; John P Pezacki; Lisa Wodicka; Amy D Brideau; Lubica Supekova; Robert Thimme; Stefan Wieland; Jens Bukh; Robert H Purcell; Peter G Schultz; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-19       Impact factor: 11.205

7.  The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity.

Authors:  Ada Staal; Julie C Frith; Michele H French; Joann Swartz; Timur Güngör; Thomas W Harrity; Joseph Tamasi; Michael J Rogers; Jean H M Feyen
Journal:  J Bone Miner Res       Date:  2003-01       Impact factor: 6.741

8.  Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c.

Authors:  Guosheng Liang; Jian Yang; Jay D Horton; Robert E Hammer; Joseph L Goldstein; Michael S Brown
Journal:  J Biol Chem       Date:  2002-01-08       Impact factor: 5.157

9.  Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line.

Authors:  V Lohmann; F Körner; J Koch; U Herian; L Theilmann; R Bartenschlager
Journal:  Science       Date:  1999-07-02       Impact factor: 47.728

10.  Regulation of PKR and IRF-1 during hepatitis C virus RNA replication.

Authors:  Jill Pflugheber; Brenda Fredericksen; Rhea Sumpter; Chunfu Wang; Felecia Ware; Donald L Sodora; Michael Gale
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

View more
  136 in total

Review 1.  SCF ubiquitin ligase-targeted therapies.

Authors:  Jeffrey R Skaar; Julia K Pagan; Michele Pagano
Journal:  Nat Rev Drug Discov       Date:  2014-11-14       Impact factor: 84.694

2.  The mevalonate pathway regulates microRNA activity in Caenorhabditis elegans.

Authors:  Zhen Shi; Gary Ruvkun
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-06       Impact factor: 11.205

3.  Probing ligand-binding pockets of the mevalonate pathway enzymes from Streptococcus pneumoniae.

Authors:  Scott T Lefurgy; Sofia B Rodriguez; Chan Sun Park; Sean Cahill; Richard B Silverman; Thomas S Leyh
Journal:  J Biol Chem       Date:  2010-04-19       Impact factor: 5.157

4.  Type I Interferon Counteracts Antiviral Effects of Statins in the Context of Gammaherpesvirus Infection.

Authors:  Philip T Lange; Eric J Darrah; Emily P Vonderhaar; Wadzanai P Mboko; Michaela M Rekow; Shailendra B Patel; Duska J Sidjanin; Vera L Tarakanova
Journal:  J Virol       Date:  2016-01-06       Impact factor: 5.103

Review 5.  Unique ties between hepatitis C virus replication and intracellular lipids.

Authors:  Eva Herker; Melanie Ott
Journal:  Trends Endocrinol Metab       Date:  2011-04-15       Impact factor: 12.015

Review 6.  Treatment failure in hepatitis C: mechanisms of non-response.

Authors:  Andrew W Tai; Raymond T Chung
Journal:  J Hepatol       Date:  2008-12-03       Impact factor: 25.083

Review 7.  Interferon-stimulated genes: a complex web of host defenses.

Authors:  William M Schneider; Meike Dittmann Chevillotte; Charles M Rice
Journal:  Annu Rev Immunol       Date:  2014-02-06       Impact factor: 28.527

8.  GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer.

Authors:  Anna-Karin M Sjogren; Karin M E Andersson; Meng Liu; Briony A Cutts; Christin Karlsson; Annika M Wahlstrom; Martin Dalin; Carolyn Weinbaum; Patrick J Casey; Andrej Tarkowski; Birgitta Swolin; Stephen G Young; Martin O Bergo
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

9.  Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication.

Authors:  Jason Borawski; Philip Troke; Xiaoling Puyang; Veronica Gibaja; Shanchaun Zhao; Craig Mickanin; Juliet Leighton-Davies; Christopher J Wilson; Vic Myer; Ivan Cornellataracido; Jeremy Baryza; John Tallarico; Gerard Joberty; Marcus Bantscheff; Markus Schirle; Tewis Bouwmeester; Joanna E Mathy; Kai Lin; Teresa Compton; Mark Labow; Brigitte Wiedmann; L Alex Gaither
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

10.  Role of cholesterol pathways in norovirus replication.

Authors:  Kyeong-Ok Chang
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.